Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Axsome Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Prev close 220.46 · gapped below the open, never looked back. High/low 213.13 at 9:30 am ET, 204.36 at 4:00 pm ET.
Axsome Therapeutics, Inc. has 9 disclosed suppliers and 3 disclosed customers. Each one is named in an SEC filing, either Axsome Therapeutics, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“In May 2022, the Company acquired the U.S. rights to SUNOSI ® (solriamfetol) from Jazz Pharmaceuticals plc ("Jazz"), and in November 2022, the Company acquired worldwide ex-U.S. rights (excluding certain Asian markets) from Jazz (collectively, the "Acquisition").”
FILING10-K0001193125-26-064267cik 0001579428
“In January 2020, the Company entered into an exclusive license agreement with Pfizer Inc. ("Pfizer") for Pfizer's clinical and non-clinical data, and intellectual property for reboxetine, the active pharmaceutical ingredient in AXS-12 which the Company is developing for the treatment of narcolepsy.”
FILING10-K0001193125-26-064267cik 0001579428
“In November 2025, Avenue announced it had entered into an agreement for Baergic to be acquired by Axsome, including the global rights to BAER-101 (also known as AZD7325), a novel oral GABAA α2,3 subtype-selective receptor positive allosteric modulator ("PAM").”
FILING10-K0001104659-26-037874cik 0001429260disclosed by FBIO
“In February 2023, the Company announced a licensing transaction with Atnahs Pharma UK Limited ("Pharmanovia") to market SUNOSI in Europe and certain countries in the Middle East / North Africa.”
FILING10-K0001193125-26-064267cik 0001579428
“Under three exclusive license agreements with Antecip, an entity owned by our Chief Executive Officer and Chairman of the Board, Herriot Tabuteau, M.D., we are obligated to make specified royalty payments ranging from 1.5% to 4.5%, subject to up to a 50% reduction depending on required payments to third parties, on net sales of our products containing the licensed technology of AXS-02, AXS-05, and AXS-04.”
FILING10-K0001193125-26-064267cik 0001579428
“in the fourth quarter of 2024, we recorded a milestone revenue of $0.5 million related to an achievement of a regulatory milestone in China for SUNOSI from SK.”
FILING10-K0001193125-26-064267cik 0001579428
“In December 2025, we acquired the global rights to deuterium-stabilized S-bupropion from DeuteRx.”
FILING10-K0001193125-26-064267cik 0001579428
“SK is the originator of SUNOSI and retains rights in 12 Asian markets, including China, Korea, and Japan.”
FILING10-K0001193125-26-064267cik 0001579428
“We also assumed the AZD7325 license agreement between Baergic and AZ.”
FILING10-K0001193125-26-064267cik 0001579428
“At the initial closing, we assumed all of the commitments of Jazz to SK and Aerial.”
FILING10-K0001193125-26-064267cik 0001579428
“In 2014, Jazz acquired from Aerial worldwide rights to SUNOSI excluding those Asian markets stated previously.”
FILING10-K0001193125-26-064267cik 0001579428
“The Company sells AUVELITY, SUNOSI, and SYMBRAVO in the United States to wholesale distributors with whom the Company has entered into formal agreements (collectively, the "Distributors").”
FILING10-K0001193125-26-064267cik 0001579428
Watchlist prices, news filtered to it, and its next report on your desk.
AXSM (Axsome Therapeutics, Inc.) has 9 disclosed suppliers and 3 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: JAZZ −1.97%, in healthcare.